Bayer’s Early R&D To Get Boost After Material Sciences Sell-Off
This article was originally published in The Tan Sheet
Germany’s diversified big pharma firm will become a bit more focused, with the goal of aiding its faster growing segments.
You may also be interested in...
Novartis stresses the blockbuster potential, in its hands, of three products – Votrient, Tafinlar and Mekinist – that it is acquiring from GSK as part of its narrowed focus on innovative pharmaceuticals, eye care and generics, and the divestment of vaccines, OTCs and animal health.
The Big Pharma intends to loosen its leash on its former animal health business come June when Pfizer shareholders will be given an option to swap their shares for Zoetis stock. Meanwhile, Pfizer continues its strategy to shift its focus back to the core pharmaceutical business.
Tschudin talked to Scrip about taking over as Novartis Pharmaceuticals president, why inclisiran is different from marketed PCSK9 inhibitors and prioritizing investment behind multiple new launches.